What’s the role of Excel in a Forecaster’s Software Toolkit?
There are many challenges that biopharma forecasters face but perhaps one of the greatest is asking people to change their behavior. No matter how many fancy forecasting tools and solutions you may have, people know what they like and one thing they like is Excel. In this video, I talk about why there is still […]
Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace
While the rapid growth of the GLP-1 and obesity market presents enormous financial opportunities for life sciences companies, it also carries legal, regulatory, and reimbursement risks. With that in mind, Norstella were recently invited to present a session at the American Conference Institute Inaugural Summit on GLP-1 Law & Policy, Using deals data from Evaluate […]
Back from BIO: The Evolving Biotech Investment Landscape
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the state of play for biotechs in recent years. Fortunately, while this may be only a partial exaggeration, there were many more positive notes as well. Fresh from my third BIO International and after digesting […]
Master patient flow analysis to predict pharma demand and provide better patient access.
Inaccurate patient flow analysis can create severe consequences even for the most diligent pharmaceutical companies. Risks include vastly overestimating or underestimating the value or opportunity for a particular product which may ultimately impact on patients’ ability to access potentially life-saving treatments. So, how can pharma companies minimize these risks and actively deliver products which support […]
Choosing the most Appropriate Time Series Algorithm for Accurate Pharmaceutical Sales Forecasts
When it comes to forecasting sales in the pharmaceutical industry, several time series algorithms are commonly used to analyze historical data and project trends into the future. These can be classified into three main types: Automated Smoothing First is the automated smoothing algorithm. This includes techniques such as growth rates and linear regression. Smoothing algorithms […]
Should Pharma Companies Really Race to be First to Market?
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […]
Three Things we Learned in our Mastering Long-Range Planning Processes Webinar
Our webinar on Long-Range Planning (LRP) forecasting took place recently and – as always – our experts Andrew Ward and Amanda Randall were on fine form. Full disclosure – this was our second webinar on this topic. You can catch up with part one – The Forecaster’s Guide to Long Range Planning here. The session […]
What makes a good (and bad) pharmaceutical forecast model
Having good forecast models is critical for effective and efficient decision-making. This will deliver accurate and reliable insights to help support business objectives and drive brand or company growth, highlight risk, and quantify opportunity. This article explores the key ingredients needed for developing good pharmaceutical forecast models. It’s widely accepted that there is no such […]
How can you Improve Efficiencies in your Long-Range Planning?
No element of pharmaceutical forecasting is easy but there’s a particular challenge in long-range planning. The range of components involved results in a greater degree of complexity which can allow inaccuracies to creep in very easily. We covered some of the key challenges in a recent webinar, The Forecaster’s Guide to Long-Range Planning, which you […]
Three Things We Learned in Our Orphan Drugs Webinar
Our recent orphan drugs webinar provided a wealth of insights into the current state and future of the orphan drug market. It was based on our annual report (which is available here) and if you missed it, I recommend taking the time to watch the on-demand version. Our panel included the report’s author, Melanie Senior […]
